

IN THE CLAIMS

1-4. (Cancelled)

5. (Currently Amended) A method for ~~treating or preventing a brain disorder~~  
diminishing a cerebral vasospasm associated with a subarachnoid hemorrhage  
comprising administering to a subject in need thereof an effective amount of an NF-  
~~κB-decoy~~ a composition comprising:

an oligonucleotide or modified oligonucleotide comprising the base sequence  
of SEQ ID NO: 1 and

a liposomal delivery system

~~which inhibits the activation of at least one gene by the NF-κB transcription~~  
~~factor, to a subject in need thereof.~~

6. (Currently Amended) The method of Claim 5, wherein said composition is  
administered intracisternally ~~brain disorder is associated with encephalopathy.~~

7. (Currently Amended) The method of Claim 5, wherein said composition is  
administered in a dose ranging from 10 to 10,000 nmoles ~~said brain disorder is~~  
~~cerebral vasospasm.~~

8. (Currently Amended) The method of Claim 5, wherein said liposomal  
delivery system is a cationic liposomal delivery system ~~said brain disorder is cerebral~~  
~~vasospasm associated with subarachnoid hemorrhage.~~

9. (Currently Amended) The method of Claim 5, wherein said liposome  
delivery system comprises a membrane fusion promoter ~~NF-κB decoy is a nucleic~~  
~~acid or an analog thereof that antagonizes the binding of nucleic acids to NF-κB.~~

10. (Currently Amended) The method of Claim 5, wherein said ~~NF-κB decoy~~  
oligonucleotide or modified oligonucleotide comprising the base sequence of SEQ ID

Appl. No.: 09/446,913  
Reply to Office Action of March 25, 2003

NO: 1 is a single-stranded oligonucleotide or modified oligonucleotide ~~nucleic acid or~~  
~~nucleic acid analog.~~

11. (Currently Amended) The method of Claim 5, wherein said ~~NF- $\kappa$ B decoy~~  
oligonucleotide or modified oligonucleotide comprising the base sequence of SEQ ID  
NO: 1 is a double-stranded oligonucleotide or modified oligonucleotide ~~nucleic acid~~  
~~or nucleic acid analog.~~

12. (Currently Amended) The method of Claim 5, wherein said ~~NF- $\kappa$ B decoy~~  
oligonucleotide or modified oligonucleotide comprising the base sequence of SEQ ID  
NO: 1 is a cyclic ~~nucleic acid or nucleic acid~~ oligonucleotide or modified  
oligonucleotide analog.

13. (Currently Amended) The method of Claim 5, wherein said ~~NF- $\kappa$ B decoy~~  
composition comprises an oligonucleotide comprising the base sequence of SEQ ID  
NO: 1 which is DNA.

14. (Currently Amended) The method of Claim 5, wherein said ~~NF- $\kappa$ B decoy~~  
is composition comprises a modified oligonucleotide comprising the base sequence of  
SEQ ID NO: 1 or a pseudonucleotide.

15. (Currently Amended) The method of Claim 5, wherein said ~~NF- $\kappa$ B decoy~~  
is composition comprises an S-oligonucleotide, an oligonucleotide in which one or  
more methyl phosphate group(s) carrying no charge has (have) been substituted for  
the phosphodiester bond, an acylated oligonucleotide, or an alkylated oligonucleotide,  
comprising the base sequence of SEQ ID NO: 1.

16. (Currently Amended) The method of Claim 5, wherein said ~~NF- $\kappa$ B decoy~~  
composition comprises multiple units of an oligonucleotide or modified  
oligonucleotide analog comprising the base sequence of SEQ ID NO: 1.

17. (Currently Amended) The method of Claim 5, wherein said ~~NF- $\kappa$ B-decoy~~ composition comprises individual units of an oligonucleotide or modified oligonucleotide comprising the base sequence of SEQ ID NO: 1.

18. (Currently Amended) A liposome comprising ~~an NF- $\kappa$ B-decoy~~ an oligonucleotide or modified oligonucleotide comprising the base sequence of SEQ ID NO: 1, ~~which inhibits the activation of at least one gene by the NF- $\kappa$ B transcription factor.~~

19. (Previously Presented) The liposome of Claim 18 that comprises a cationic lipid.

20. (Previously Presented) The liposome of Claim 18 that comprises a membrane-fusion promoter.

21. (Previously Presented) The liposome of Claim 18 that comprises a large unilamellar vesicle (LUV) structure.

22. (Previously Presented) The liposome of Claim 18 that comprises a multilamellar vesicle (MLV) structure.

23. (Previously Presented) The liposome of Claim 18 that comprises a small unilamellar vesicle (SUV) structure.

24. (Currently Amended) A method for ~~treating or preventing a brain disorder~~ diminishing a cerebral vasospasm associated with a subarachnoid hemorrhage comprising administering an effective amount of the liposome of Claim 18 to a subject in need thereof.